Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
10.1038/s41581-020-00369-0 245 TaoS.LiL.LiL.LiuY.RenQ.ShiM.et al (2019)
For weight management in people without diabetes, NICE recommends considering specific GLP-1 agonists (semaglutide 2.4mg or liraglutide 3mg) only in specialist weight management services, for individuals with a BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Black African, or African-Caribbean backgrounds) who have weight-related comorbidities
Two of these have been approved for market: Novo Nordisks GCGR agonist, Glucagon, and Eli Lillys GCGR agonist, Glucagon
Your BodyLogicMD provider will consider your medical history, current health status, and treatment goals when determining whether GLP-1 shots are right for you
Typical outcomes include around 10 to 15 percent weight loss and about a 1 percent HbA1c reduction
